Mymetics to Present New Preclinical Data on Thermostable and Cold-Chain Independent Virosome based Vaccines
Epalinges, Switzerland, September 13, 2017 – Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases, announced today that they will present new preclinical data. The new data demonstrates that nasal powder, oral capsules and sublingual tablets developed by MACIVIVA partners, containing Mymetics HIV-1 virosome based vaccine candidate, could induce specific antibody immune response in rodent and mini-pig animal models.
| Media Name | Media Type | Description | Download |
|---|---|---|---|
| Presse release | Download |